1
|
Tang H, Miao X, Yu C, Chai C, Su Y, Li L, Yi J, Ye Z, Miao L, Wang Z, Zhang H, Xu H, Zhou W. A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma. Sci Rep 2024; 14:9259. [PMID: 38649719 PMCID: PMC11035558 DOI: 10.1038/s41598-024-56464-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2024] [Accepted: 03/06/2024] [Indexed: 04/25/2024] Open
Abstract
Chemotherapy resistance poses clinical challenges in pancreatic cancer treatment. Developing cell lines resistant to chemotherapy is crucial for investigating drug resistance mechanisms and identifying alternative treatment pathways. The genetic and biological attributes of pancreatic cancer depend on its aetiology, racial demographics and anatomical origin, underscoring the need for models that comprehensively represent these characteristics. Here, we introduce PDAC-X2, a pancreatic cancer cell line derived from Chinese patients. We conducted a comprehensive analysis encompassing the immune phenotype, biology, genetics, molecular characteristics and tumorigenicity of the cell line. PDAC-X2 cells displayed epithelial morphology and expressed cell markers (CK7 and CK19) alongside other markers (E-cadherin, Vimentin, Ki-67, CEA and CA19-9). The population doubling time averaged around 69 h. In vivo, PDAC-X2 cells consistently maintained their tumorigenicity, achieving a 100% tumour formation rate. Characterised by a predominantly tetraploid karyotype, this cell line exhibited a complex genetic markup. Notably, PDAC-X2 cells demonstrated resistance to multiple drugs, including gemcitabine, paclitaxel, 5-fluorouracil and oxaliplatin. In conclusion, PDAC-X2 presents an invaluable preclinical model. Its utility lies in facilitating the study of drug resistance mechanisms and the exploration of alternative therapeutic approaches aimed at enhancing the prognosis of this tumour type.
Collapse
Affiliation(s)
- Huan Tang
- The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China
| | - Xin Miao
- The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310006, China
| | - Cheng Yu
- The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China
- Department of Anesthesiology, Lanzhou University Second Hospital, Lanzhou, 730000, China
| | - Changpeng Chai
- The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou, 730000, China
| | - Yuanhui Su
- The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China
| | - Lu Li
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou, 730000, China
| | - Jianfeng Yi
- The First Clinical Medical School of Lanzhou University, Lanzhou, 730000, China
- The First School of Clinical Medicine of Gansu University of Chinese Medicine, Lanzhou, 730000, China
| | - Zhenzhen Ye
- The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China
- The First School of Clinical Medicine of Gansu University of Chinese Medicine, Lanzhou, 730000, China
| | - Long Miao
- The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou, 730000, China
| | - Zhengfeng Wang
- The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou, 730000, China
| | - Hui Zhang
- The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China.
- Department of General Surgery, Lanzhou University Second Hospital, No. 82 Cuiyingmen, Chengguan District, Lanzhou, 730000, Gansu, China.
| | - Hao Xu
- The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310006, China.
- Department of Hepatobiliary Surgery, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, 310006, China.
| | - Wence Zhou
- The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China.
- Department of General Surgery, Lanzhou University Second Hospital, No. 82 Cuiyingmen, Chengguan District, Lanzhou, 730000, Gansu, China.
| |
Collapse
|